84 related articles for article (PubMed ID: 12764671)
1. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Ralph LD; Thomson AH; Dobbs NA; Twelves C
Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
[TBL] [Abstract][Full Text] [Related]
2. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
3. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.
Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U
Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the validity of a population pharmacokinetic model for epirubicin.
Ralph LD; Sandstrom M; Twelves C; Dobbs NA; Thomson AH
Br J Clin Pharmacol; 2006 Jul; 62(1):47-55. PubMed ID: 16842378
[TBL] [Abstract][Full Text] [Related]
9. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
Dobbs NA; Twelves CJ; Gregory W; Cruickshanka C; Richards MA; Rubens RD
Eur J Cancer; 2003 Mar; 39(5):580-6. PubMed ID: 12628836
[TBL] [Abstract][Full Text] [Related]
10. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
14. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer.
Deporte-Fety R; Simon N; Fumoleau P; Campone M; Kerbrat P; Bonneterre J; Fargeot P; Urien S
Cancer Chemother Pharmacol; 2004 Mar; 53(3):233-8. PubMed ID: 14634791
[TBL] [Abstract][Full Text] [Related]
18. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
20. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
